Large scale meta-analysis of preclinical toxicity data for target characterisation and hypotheses generation.
| Autor: | Munoz-Muriedas J; Computational Toxicology, Data and Computational Sciences, GlaxoSmithKline, London, United Kingdom. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | PloS one [PLoS One] 2021 Jun 08; Vol. 16 (6), pp. e0252533. Date of Electronic Publication: 2021 Jun 08 (Print Publication: 2021). |
| DOI: | 10.1371/journal.pone.0252533 |
| Abstrakt: | Recent technological advances in the field of big data have increased our capabilities to query large databases and combine information from different domains and disciplines. In the area of preclinical studies, initiatives like SEND (Standard for Exchange of Nonclinical Data) will also contribute to collect and present nonclinical data in a consistent manner and increase analytical possibilities. With facilitated access to preclinical data and improvements in analytical algorithms there will surely be an expectation for organisations to ensure all the historical data available to them is leveraged to build new hypotheses. These kinds of analyses may soon become as important as the animal studies themselves, in addition to being critical components to achieve objectives aligned with 3Rs. This article proposes the application of meta-analyses at large scale in corporate databases as a tool to exploit data from both preclinical studies and in vitro pharmacological activity assays to identify associations between targets and tissues that can be used as seeds for the development of causal hypotheses to characterise of targets. A total of 833 in-house preclinical toxicity studies relating to 416 compounds reported to be active (pXC50 ≥ 5.5) against a panel of 96 selected targets of interest for potential off-target non desired effects were meta-analysed, aggregating the data in tissue-target pairs. The primary outcome was the odds ratio (OR) of the number of animals with observed events (any morphology, any severity) in treated and control groups in the tissue analysed. This led to a total of 2139 meta-analyses producing a total of 364 statistically significant associations (random effects model), 121 after adjusting by multiple comparison bias. The results show the utility of the proposed approach to leverage historical corporate data and may offer a vehicle for researchers to share, aggregate and analyse their preclinical toxicological data in precompetitive environments. Competing Interests: Jordi Munoz-Muriedas is a full-time employee of GlaxoSmithKline. Jordi Munoz-Muriedas has no other competing interests in relation to other companies, organisations or persons. GlaxoSmithKline is a global healthcare company with a portfolio of medicines in respiratory, HIV, immune-inflammatory and oncology therapeutic areas in addition to vaccines and healthcare products. Jordi Munoz-Muriedas confirms his commercial affiliation does not alter his adherence to all PLOS ONE policies on sharing data and materials. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|